| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 21 | 2023 | 432 | 2.780 |
Why?
|
| Rhinitis | 22 | 2023 | 383 | 2.710 |
Why?
|
| Head and Neck Neoplasms | 17 | 2022 | 561 | 2.700 |
Why?
|
| Sleep Apnea, Obstructive | 18 | 2022 | 142 | 2.580 |
Why?
|
| Endoscopy | 15 | 2022 | 464 | 2.180 |
Why?
|
| Carcinoma, Squamous Cell | 20 | 2022 | 629 | 2.150 |
Why?
|
| Humans | 254 | 2023 | 68618 | 1.740 |
Why?
|
| Quality of Life | 24 | 2022 | 1515 | 1.720 |
Why?
|
| Dilatation | 6 | 2022 | 58 | 1.720 |
Why?
|
| Hearing Loss | 12 | 2022 | 154 | 1.590 |
Why?
|
| Coronavirus Infections | 5 | 2020 | 143 | 1.580 |
Why?
|
| Pneumonia, Viral | 5 | 2020 | 154 | 1.570 |
Why?
|
| Eustachian Tube | 6 | 2022 | 31 | 1.550 |
Why?
|
| Ear Diseases | 6 | 2022 | 37 | 1.540 |
Why?
|
| Retrospective Studies | 91 | 2023 | 7277 | 1.490 |
Why?
|
| Parotid Neoplasms | 11 | 2020 | 49 | 1.390 |
Why?
|
| Treatment Outcome | 68 | 2022 | 7029 | 1.390 |
Why?
|
| Cochlear Implantation | 9 | 2023 | 99 | 1.380 |
Why?
|
| Male | 143 | 2023 | 37321 | 1.350 |
Why?
|
| Middle Aged | 107 | 2022 | 21147 | 1.330 |
Why?
|
| Female | 142 | 2023 | 38074 | 1.320 |
Why?
|
| Adult | 96 | 2023 | 21403 | 1.310 |
Why?
|
| Aged | 85 | 2022 | 14862 | 1.270 |
Why?
|
| Cochlear Implants | 8 | 2023 | 110 | 1.180 |
Why?
|
| Child | 53 | 2023 | 6405 | 1.180 |
Why?
|
| Aged, 80 and over | 47 | 2022 | 4848 | 1.100 |
Why?
|
| Oropharyngeal Neoplasms | 9 | 2022 | 94 | 1.050 |
Why?
|
| Child, Preschool | 38 | 2022 | 3187 | 1.040 |
Why?
|
| Postoperative Complications | 19 | 2022 | 1615 | 1.040 |
Why?
|
| Betacoronavirus | 4 | 2020 | 116 | 1.000 |
Why?
|
| Sialadenitis | 3 | 2014 | 3 | 0.990 |
Why?
|
| Rhinitis, Allergic | 4 | 2021 | 22 | 0.980 |
Why?
|
| Tonsillectomy | 7 | 2022 | 69 | 0.970 |
Why?
|
| Paranasal Sinuses | 10 | 2023 | 165 | 0.970 |
Why?
|
| Adolescent | 48 | 2022 | 8912 | 0.960 |
Why?
|
| Olfaction Disorders | 7 | 2022 | 100 | 0.930 |
Why?
|
| Young Adult | 40 | 2022 | 5717 | 0.930 |
Why?
|
| Pandemics | 6 | 2021 | 352 | 0.920 |
Why?
|
| Chronic Disease | 26 | 2023 | 1330 | 0.900 |
Why?
|
| Hearing Loss, Sensorineural | 7 | 2020 | 110 | 0.900 |
Why?
|
| Prospective Studies | 29 | 2021 | 3705 | 0.850 |
Why?
|
| Salivary Glands | 5 | 2018 | 52 | 0.850 |
Why?
|
| Nasal Polyps | 7 | 2023 | 184 | 0.850 |
Why?
|
| Vestibular Neuronitis | 1 | 2022 | 2 | 0.850 |
Why?
|
| Registries | 7 | 2018 | 733 | 0.820 |
Why?
|
| Adenoidectomy | 8 | 2022 | 51 | 0.810 |
Why?
|
| Infant | 32 | 2022 | 2891 | 0.810 |
Why?
|
| Tinnitus | 5 | 2021 | 22 | 0.770 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2022 | 186 | 0.770 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 26 | 0.710 |
Why?
|
| Survivorship | 1 | 2020 | 20 | 0.710 |
Why?
|
| Salivary Gland Neoplasms | 4 | 2021 | 40 | 0.700 |
Why?
|
| Anti-Infective Agents, Local | 3 | 2021 | 40 | 0.700 |
Why?
|
| Tomography, X-Ray Computed | 18 | 2023 | 2324 | 0.680 |
Why?
|
| Down Syndrome | 5 | 2018 | 120 | 0.680 |
Why?
|
| Catheterization | 2 | 2017 | 209 | 0.660 |
Why?
|
| Mouth Neoplasms | 6 | 2020 | 206 | 0.650 |
Why?
|
| Papillomavirus Infections | 5 | 2022 | 194 | 0.630 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 8 | 2021 | 62 | 0.620 |
Why?
|
| Meniere Disease | 5 | 2022 | 31 | 0.620 |
Why?
|
| Transplantation Conditioning | 2 | 2017 | 34 | 0.620 |
Why?
|
| Nasal Obstruction | 4 | 2022 | 34 | 0.600 |
Why?
|
| Velopharyngeal Insufficiency | 4 | 2019 | 14 | 0.600 |
Why?
|
| SEER Program | 10 | 2021 | 153 | 0.590 |
Why?
|
| Speech Perception | 6 | 2021 | 261 | 0.590 |
Why?
|
| Neoplasm Staging | 13 | 2021 | 800 | 0.590 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2017 | 21 | 0.590 |
Why?
|
| Survival Rate | 16 | 2021 | 1056 | 0.580 |
Why?
|
| Staphylococcus aureus | 3 | 2017 | 175 | 0.580 |
Why?
|
| Dizziness | 4 | 2021 | 27 | 0.580 |
Why?
|
| Killer Cells, Natural | 1 | 2017 | 94 | 0.570 |
Why?
|
| Snoring | 3 | 2015 | 8 | 0.570 |
Why?
|
| Staphylococcal Infections | 2 | 2017 | 156 | 0.560 |
Why?
|
| Parotid Gland | 7 | 2021 | 33 | 0.550 |
Why?
|
| Skull Base | 4 | 2019 | 72 | 0.550 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2017 | 116 | 0.540 |
Why?
|
| Hearing Tests | 8 | 2021 | 70 | 0.530 |
Why?
|
| Carcinoma, Acinar Cell | 3 | 2021 | 14 | 0.530 |
Why?
|
| Deafness | 3 | 2022 | 64 | 0.530 |
Why?
|
| Dysphonia | 2 | 2020 | 6 | 0.530 |
Why?
|
| Databases, Factual | 14 | 2020 | 622 | 0.520 |
Why?
|
| Orbital Diseases | 3 | 2020 | 21 | 0.520 |
Why?
|
| Continuous Positive Airway Pressure | 4 | 2021 | 33 | 0.510 |
Why?
|
| Length of Stay | 8 | 2020 | 780 | 0.510 |
Why?
|
| Risk Factors | 23 | 2022 | 5731 | 0.510 |
Why?
|
| Desensitization, Immunologic | 2 | 2014 | 25 | 0.500 |
Why?
|
| Prognosis | 21 | 2022 | 2093 | 0.500 |
Why?
|
| Congenital Abnormalities | 3 | 2020 | 42 | 0.500 |
Why?
|
| Organ Sparing Treatments | 1 | 2014 | 3 | 0.500 |
Why?
|
| Otolaryngology | 3 | 2020 | 38 | 0.500 |
Why?
|
| Papillomaviridae | 6 | 2022 | 104 | 0.490 |
Why?
|
| Hearing Loss, Noise-Induced | 3 | 2021 | 46 | 0.490 |
Why?
|
| Neuroma, Acoustic | 3 | 2019 | 17 | 0.480 |
Why?
|
| Nasal Lavage | 1 | 2014 | 6 | 0.480 |
Why?
|
| Otitis Externa | 3 | 2020 | 14 | 0.480 |
Why?
|
| Alcohols | 1 | 2014 | 13 | 0.480 |
Why?
|
| Pituitary Neoplasms | 3 | 2020 | 52 | 0.460 |
Why?
|
| Carrier State | 1 | 2014 | 39 | 0.460 |
Why?
|
| Deglutition Disorders | 4 | 2023 | 297 | 0.460 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2018 | 468 | 0.460 |
Why?
|
| Recovery of Function | 1 | 2017 | 506 | 0.460 |
Why?
|
| Nasal Mucosa | 1 | 2014 | 68 | 0.450 |
Why?
|
| Follow-Up Studies | 16 | 2019 | 3259 | 0.450 |
Why?
|
| Sleep Apnea Syndromes | 2 | 2020 | 40 | 0.450 |
Why?
|
| Glossectomy | 3 | 2020 | 9 | 0.450 |
Why?
|
| Age Factors | 9 | 2021 | 1864 | 0.450 |
Why?
|
| Ethanol | 4 | 2012 | 893 | 0.450 |
Why?
|
| Risk Assessment | 10 | 2020 | 2007 | 0.440 |
Why?
|
| Cognitive Dysfunction | 3 | 2021 | 176 | 0.430 |
Why?
|
| Otitis Media | 4 | 2022 | 35 | 0.430 |
Why?
|
| Immunization Schedule | 1 | 2012 | 25 | 0.420 |
Why?
|
| Vaccination | 2 | 2023 | 189 | 0.420 |
Why?
|
| Parotid Diseases | 3 | 2018 | 3 | 0.420 |
Why?
|
| Prevalence | 14 | 2021 | 1619 | 0.420 |
Why?
|
| Anesthetics, Intravenous | 1 | 2012 | 27 | 0.420 |
Why?
|
| Travel | 1 | 2012 | 38 | 0.420 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2022 | 446 | 0.410 |
Why?
|
| Salivary Gland Calculi | 3 | 2018 | 4 | 0.400 |
Why?
|
| Foreign Bodies | 2 | 2022 | 58 | 0.400 |
Why?
|
| Health Care Costs | 3 | 2020 | 346 | 0.390 |
Why?
|
| Reoperation | 6 | 2019 | 467 | 0.390 |
Why?
|
| Vertigo | 5 | 2020 | 24 | 0.390 |
Why?
|
| Surveys and Questionnaires | 12 | 2022 | 2800 | 0.390 |
Why?
|
| Triiodobenzoic Acids | 2 | 2008 | 28 | 0.390 |
Why?
|
| Eyelid Neoplasms | 2 | 2022 | 12 | 0.390 |
Why?
|
| Cholesteatoma, Middle Ear | 2 | 2022 | 9 | 0.390 |
Why?
|
| Ear, Middle | 4 | 2021 | 32 | 0.390 |
Why?
|
| Migraine Disorders | 3 | 2021 | 66 | 0.390 |
Why?
|
| Taste | 1 | 2011 | 49 | 0.390 |
Why?
|
| Nose Deformities, Acquired | 2 | 2021 | 6 | 0.380 |
Why?
|
| Hypersensitivity | 1 | 2011 | 52 | 0.380 |
Why?
|
| Sirolimus | 1 | 2012 | 118 | 0.380 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 118 | 0.380 |
Why?
|
| Iohexol | 2 | 2008 | 82 | 0.380 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2021 | 12 | 0.380 |
Why?
|
| United States | 22 | 2020 | 7367 | 0.380 |
Why?
|
| Vestibule, Labyrinth | 2 | 2021 | 19 | 0.370 |
Why?
|
| Laryngoscopy | 4 | 2020 | 61 | 0.360 |
Why?
|
| Electric Stimulation Therapy | 3 | 2018 | 147 | 0.360 |
Why?
|
| Time-to-Treatment | 3 | 2020 | 117 | 0.360 |
Why?
|
| Palate, Soft | 2 | 2012 | 12 | 0.360 |
Why?
|
| Neurosurgical Procedures | 4 | 2020 | 98 | 0.350 |
Why?
|
| Xerostomia | 3 | 2015 | 24 | 0.350 |
Why?
|
| Pulmonary Veins | 2 | 2009 | 56 | 0.350 |
Why?
|
| Natural Orifice Endoscopic Surgery | 2 | 2020 | 24 | 0.350 |
Why?
|
| Pulmonary Embolism | 2 | 2009 | 253 | 0.350 |
Why?
|
| Alphapapillomavirus | 2 | 2020 | 17 | 0.350 |
Why?
|
| Urban Health Services | 1 | 2009 | 24 | 0.350 |
Why?
|
| Transcutaneous Electric Nerve Stimulation | 2 | 2020 | 40 | 0.350 |
Why?
|
| Ear Canal | 2 | 2022 | 24 | 0.340 |
Why?
|
| Skin Neoplasms | 3 | 2021 | 375 | 0.340 |
Why?
|
| Phlebography | 1 | 2009 | 31 | 0.340 |
Why?
|
| Durapatite | 1 | 2009 | 33 | 0.340 |
Why?
|
| Vocal Cord Paralysis | 1 | 2009 | 18 | 0.340 |
Why?
|
| Ear, Inner | 2 | 2022 | 47 | 0.340 |
Why?
|
| Radiation Injuries | 3 | 2015 | 97 | 0.330 |
Why?
|
| Carcinoma, Mucoepidermoid | 2 | 2020 | 14 | 0.330 |
Why?
|
| Alcoholism | 3 | 2007 | 1109 | 0.330 |
Why?
|
| Physician Assistants | 1 | 2009 | 47 | 0.330 |
Why?
|
| Laryngeal Neoplasms | 1 | 2009 | 47 | 0.330 |
Why?
|
| Cohort Studies | 14 | 2021 | 2358 | 0.330 |
Why?
|
| Smell | 5 | 2022 | 131 | 0.320 |
Why?
|
| Lymphatic Metastasis | 6 | 2022 | 274 | 0.320 |
Why?
|
| Nipecotic Acids | 2 | 2005 | 11 | 0.320 |
Why?
|
| Voice | 2 | 2020 | 16 | 0.320 |
Why?
|
| Rural Health Services | 1 | 2009 | 101 | 0.320 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2021 | 756 | 0.320 |
Why?
|
| Quality Improvement | 5 | 2023 | 413 | 0.320 |
Why?
|
| Airway Obstruction | 2 | 2021 | 49 | 0.320 |
Why?
|
| Severity of Illness Index | 11 | 2021 | 1851 | 0.320 |
Why?
|
| Antineoplastic Agents | 3 | 2012 | 1070 | 0.310 |
Why?
|
| Skin Diseases | 1 | 2009 | 122 | 0.310 |
Why?
|
| Venous Thrombosis | 1 | 2009 | 125 | 0.310 |
Why?
|
| Hyperbaric Oxygenation | 2 | 2020 | 11 | 0.310 |
Why?
|
| Neck Dissection | 4 | 2022 | 55 | 0.310 |
Why?
|
| Palate | 3 | 2017 | 14 | 0.310 |
Why?
|
| Anxiety | 2 | 2022 | 422 | 0.310 |
Why?
|
| Cross-Sectional Studies | 10 | 2022 | 2279 | 0.300 |
Why?
|
| Prostheses and Implants | 1 | 2009 | 159 | 0.300 |
Why?
|
| Robotic Surgical Procedures | 2 | 2020 | 49 | 0.300 |
Why?
|
| Creatinine | 1 | 2008 | 243 | 0.300 |
Why?
|
| Depression | 3 | 2020 | 943 | 0.300 |
Why?
|
| Publishing | 2 | 2019 | 89 | 0.290 |
Why?
|
| Doxycycline | 2 | 2017 | 49 | 0.290 |
Why?
|
| Biocompatible Materials | 1 | 2009 | 247 | 0.290 |
Why?
|
| Glomerular Filtration Rate | 1 | 2008 | 274 | 0.290 |
Why?
|
| Precancerous Conditions | 2 | 2020 | 74 | 0.290 |
Why?
|
| DiGeorge Syndrome | 2 | 2017 | 13 | 0.290 |
Why?
|
| Nasal Surgical Procedures | 3 | 2018 | 21 | 0.290 |
Why?
|
| Ossicular Prosthesis | 2 | 2018 | 10 | 0.290 |
Why?
|
| Pharynx | 2 | 2019 | 89 | 0.290 |
Why?
|
| Prosthesis-Related Infections | 2 | 2017 | 70 | 0.280 |
Why?
|
| Cleft Lip | 2 | 2019 | 33 | 0.280 |
Why?
|
| Fructose | 1 | 2007 | 51 | 0.280 |
Why?
|
| Polysomnography | 8 | 2022 | 92 | 0.280 |
Why?
|
| Patient Readmission | 3 | 2019 | 267 | 0.280 |
Why?
|
| Incidence | 9 | 2021 | 1603 | 0.280 |
Why?
|
| Thyroid Neoplasms | 2 | 2020 | 68 | 0.270 |
Why?
|
| Facial Nerve | 2 | 2017 | 25 | 0.270 |
Why?
|
| Comorbidity | 9 | 2022 | 1426 | 0.270 |
Why?
|
| Temporal Bone | 4 | 2022 | 53 | 0.270 |
Why?
|
| Surgical Flaps | 2 | 2019 | 120 | 0.270 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2022 | 148 | 0.270 |
Why?
|
| Ossicular Replacement | 2 | 2016 | 7 | 0.270 |
Why?
|
| Contrast Media | 5 | 2010 | 595 | 0.260 |
Why?
|
| Neoplasm Invasiveness | 4 | 2021 | 369 | 0.260 |
Why?
|
| Disease-Free Survival | 5 | 2018 | 349 | 0.250 |
Why?
|
| Kidney Diseases | 1 | 2008 | 307 | 0.250 |
Why?
|
| Thyroid Nodule | 2 | 2017 | 15 | 0.250 |
Why?
|
| Reinforcement Schedule | 1 | 2005 | 59 | 0.250 |
Why?
|
| Infant, Newborn | 10 | 2022 | 2455 | 0.250 |
Why?
|
| Combined Modality Therapy | 10 | 2021 | 951 | 0.250 |
Why?
|
| Obesity | 3 | 2018 | 1076 | 0.240 |
Why?
|
| Auditory Threshold | 4 | 2022 | 206 | 0.240 |
Why?
|
| Audiometry, Pure-Tone | 6 | 2022 | 96 | 0.240 |
Why?
|
| Mastoidectomy | 2 | 2022 | 7 | 0.240 |
Why?
|
| Glottis | 2 | 2016 | 17 | 0.230 |
Why?
|
| Laryngomalacia | 2 | 2016 | 12 | 0.230 |
Why?
|
| Cerebrospinal Fluid Leak | 3 | 2020 | 32 | 0.230 |
Why?
|
| Otolaryngologists | 2 | 2021 | 5 | 0.230 |
Why?
|
| Personal Protective Equipment | 2 | 2021 | 27 | 0.230 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2009 | 767 | 0.230 |
Why?
|
| Hypoglossal Nerve | 3 | 2018 | 5 | 0.220 |
Why?
|
| Hypopharyngeal Neoplasms | 2 | 2016 | 10 | 0.220 |
Why?
|
| Graft vs Host Disease | 2 | 2017 | 163 | 0.220 |
Why?
|
| Weight Gain | 2 | 2017 | 135 | 0.220 |
Why?
|
| Reward | 1 | 2005 | 201 | 0.220 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 2 | 2020 | 18 | 0.220 |
Why?
|
| Defibrillators, Implantable | 2 | 2018 | 329 | 0.220 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2017 | 245 | 0.220 |
Why?
|
| Cochlea | 3 | 2022 | 169 | 0.220 |
Why?
|
| Tracheostomy | 2 | 2020 | 31 | 0.210 |
Why?
|
| Cerebrospinal Fluid Otorrhea | 2 | 2014 | 15 | 0.210 |
Why?
|
| Global Health | 2 | 2020 | 136 | 0.210 |
Why?
|
| Cholesteatoma | 1 | 2022 | 4 | 0.210 |
Why?
|
| Pneumococcal Infections | 1 | 2023 | 30 | 0.210 |
Why?
|
| Asthma | 3 | 2017 | 345 | 0.210 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2022 | 30 | 0.210 |
Why?
|
| Survival Analysis | 8 | 2018 | 714 | 0.210 |
Why?
|
| Spinal Diseases | 1 | 2023 | 53 | 0.210 |
Why?
|
| Osteomyelitis | 1 | 2022 | 40 | 0.210 |
Why?
|
| Tracheoesophageal Fistula | 1 | 2022 | 15 | 0.210 |
Why?
|
| Melanoma | 2 | 2018 | 335 | 0.210 |
Why?
|
| Cerebrovascular Trauma | 1 | 2022 | 7 | 0.210 |
Why?
|
| Hemangioma, Capillary | 1 | 2022 | 6 | 0.210 |
Why?
|
| Carotid Artery Injuries | 1 | 2022 | 26 | 0.210 |
Why?
|
| Endolymphatic Hydrops | 1 | 2022 | 4 | 0.210 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2022 | 13 | 0.200 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2022 | 18 | 0.200 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2022 | 16 | 0.200 |
Why?
|
| Cleft Palate | 1 | 2022 | 34 | 0.200 |
Why?
|
| Congenital Hypothyroidism | 1 | 2022 | 6 | 0.200 |
Why?
|
| Asthma, Aspirin-Induced | 1 | 2021 | 4 | 0.200 |
Why?
|
| Anesthesia, General | 1 | 2022 | 86 | 0.200 |
Why?
|
| Prosthesis Implantation | 2 | 2015 | 83 | 0.200 |
Why?
|
| Neuromuscular Agents | 2 | 2012 | 22 | 0.200 |
Why?
|
| Encephalocele | 2 | 2020 | 30 | 0.200 |
Why?
|
| Hemangioma | 1 | 2022 | 51 | 0.200 |
Why?
|
| Biomedical Research | 1 | 2005 | 310 | 0.200 |
Why?
|
| Lip Neoplasms | 1 | 2021 | 12 | 0.200 |
Why?
|
| Botulinum Toxins, Type A | 2 | 2012 | 31 | 0.200 |
Why?
|
| Pierre Robin Syndrome | 1 | 2021 | 7 | 0.190 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2021 | 22 | 0.190 |
Why?
|
| Administration, Intranasal | 3 | 2021 | 88 | 0.190 |
Why?
|
| Osteogenesis, Distraction | 1 | 2021 | 13 | 0.190 |
Why?
|
| Peripheral Nerves | 1 | 2021 | 22 | 0.190 |
Why?
|
| Sebaceous Gland Neoplasms | 1 | 2021 | 4 | 0.190 |
Why?
|
| Thyroid Diseases | 2 | 2011 | 33 | 0.190 |
Why?
|
| Rhinitis, Allergic, Perennial | 1 | 2021 | 43 | 0.190 |
Why?
|
| Virus Diseases | 1 | 2021 | 31 | 0.190 |
Why?
|
| Clinical Competence | 2 | 2020 | 657 | 0.190 |
Why?
|
| Time Factors | 12 | 2019 | 4655 | 0.190 |
Why?
|
| Patient Satisfaction | 3 | 2019 | 378 | 0.190 |
Why?
|
| Cause of Death | 2 | 2013 | 241 | 0.190 |
Why?
|
| Pilot Projects | 3 | 2015 | 1342 | 0.180 |
Why?
|
| Laryngoplasty | 1 | 2020 | 8 | 0.180 |
Why?
|
| Hearing Loss, Unilateral | 1 | 2020 | 7 | 0.180 |
Why?
|
| Carcinoma, Papillary | 1 | 2020 | 35 | 0.180 |
Why?
|
| Hypocalcemia | 1 | 2020 | 13 | 0.180 |
Why?
|
| Anti-Bacterial Agents | 2 | 2017 | 1026 | 0.180 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 47 | 0.180 |
Why?
|
| Loneliness | 1 | 2020 | 20 | 0.180 |
Why?
|
| Population Groups | 1 | 2020 | 16 | 0.180 |
Why?
|
| Carcinoma | 2 | 2019 | 215 | 0.180 |
Why?
|
| Vestibular Diseases | 1 | 2020 | 11 | 0.180 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2020 | 10 | 0.180 |
Why?
|
| Voice Disorders | 1 | 2020 | 22 | 0.180 |
Why?
|
| Allografts | 2 | 2017 | 63 | 0.180 |
Why?
|
| Craniopharyngioma | 1 | 2020 | 7 | 0.180 |
Why?
|
| Central Nervous System Cysts | 1 | 2020 | 5 | 0.180 |
Why?
|
| Larynx | 1 | 2020 | 49 | 0.180 |
Why?
|
| Cranial Fossa, Anterior | 1 | 2020 | 8 | 0.180 |
Why?
|
| Esophagoscopy | 1 | 2020 | 72 | 0.180 |
Why?
|
| Marfan Syndrome | 1 | 2020 | 42 | 0.180 |
Why?
|
| Carcinoma in Situ | 1 | 2020 | 47 | 0.180 |
Why?
|
| Social Isolation | 1 | 2020 | 40 | 0.180 |
Why?
|
| Respiratory Therapy | 1 | 2020 | 24 | 0.170 |
Why?
|
| Bone Conduction | 2 | 2016 | 9 | 0.170 |
Why?
|
| Chromosome Disorders | 1 | 2020 | 31 | 0.170 |
Why?
|
| Nose | 4 | 2022 | 36 | 0.170 |
Why?
|
| Bibliometrics | 1 | 2019 | 25 | 0.170 |
Why?
|
| Surgery, Plastic | 1 | 2019 | 14 | 0.170 |
Why?
|
| Mastoid | 2 | 2022 | 20 | 0.170 |
Why?
|
| Adenoma, Pleomorphic | 1 | 2019 | 10 | 0.170 |
Why?
|
| Hearing | 4 | 2021 | 133 | 0.170 |
Why?
|
| Malnutrition | 1 | 2020 | 28 | 0.170 |
Why?
|
| Video Recording | 1 | 2020 | 145 | 0.170 |
Why?
|
| Carcinosarcoma | 1 | 2019 | 12 | 0.170 |
Why?
|
| Nasal Cavity | 2 | 2021 | 62 | 0.170 |
Why?
|
| Skull Base Neoplasms | 1 | 2019 | 13 | 0.170 |
Why?
|
| Geriatric Assessment | 1 | 2020 | 107 | 0.170 |
Why?
|
| Safety Management | 1 | 2020 | 73 | 0.170 |
Why?
|
| Hydroxychloroquine | 1 | 2019 | 14 | 0.170 |
Why?
|
| Central Nervous System Diseases | 1 | 2019 | 40 | 0.170 |
Why?
|
| Choanal Atresia | 1 | 2019 | 5 | 0.170 |
Why?
|
| GTP Phosphohydrolases | 2 | 2017 | 46 | 0.170 |
Why?
|
| Pneumonia | 1 | 2020 | 110 | 0.170 |
Why?
|
| Pregnancy in Diabetics | 1 | 2020 | 70 | 0.170 |
Why?
|
| Placebos | 3 | 2014 | 195 | 0.170 |
Why?
|
| Anesthesia | 1 | 2020 | 120 | 0.170 |
Why?
|
| Cicatrix | 1 | 2019 | 60 | 0.170 |
Why?
|
| Coronary Angiography | 4 | 2008 | 866 | 0.160 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2017 | 78 | 0.160 |
Why?
|
| Antirheumatic Agents | 1 | 2019 | 59 | 0.160 |
Why?
|
| Brain Diseases | 1 | 2019 | 78 | 0.160 |
Why?
|
| Alcohol Drinking | 1 | 2005 | 805 | 0.160 |
Why?
|
| Endoscopes | 1 | 2018 | 36 | 0.160 |
Why?
|
| Adenoma | 1 | 2020 | 132 | 0.160 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 1 | 2018 | 4 | 0.160 |
Why?
|
| France | 3 | 2015 | 26 | 0.160 |
Why?
|
| Bacterial Infections | 1 | 2020 | 163 | 0.160 |
Why?
|
| Bronchoscopy | 1 | 2020 | 147 | 0.160 |
Why?
|
| Esophagogastric Junction | 1 | 2018 | 118 | 0.160 |
Why?
|
| Otorhinolaryngologic Diseases | 1 | 2018 | 14 | 0.160 |
Why?
|
| Ear Neoplasms | 1 | 2018 | 13 | 0.160 |
Why?
|
| Administration, Oral | 4 | 2017 | 411 | 0.160 |
Why?
|
| Cryotherapy | 1 | 2018 | 36 | 0.160 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 12 | 0.160 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 18 | 0.160 |
Why?
|
| Stomach Neoplasms | 1 | 2018 | 64 | 0.150 |
Why?
|
| Iopamidol | 2 | 2008 | 37 | 0.150 |
Why?
|
| Patient Safety | 1 | 2020 | 202 | 0.150 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2018 | 99 | 0.150 |
Why?
|
| Case-Control Studies | 5 | 2023 | 1553 | 0.150 |
Why?
|
| Neurotology | 1 | 2018 | 7 | 0.150 |
Why?
|
| Viral Vaccines | 2 | 2020 | 17 | 0.150 |
Why?
|
| Hearing Aids | 1 | 2018 | 34 | 0.150 |
Why?
|
| Health Status Indicators | 1 | 2018 | 117 | 0.150 |
Why?
|
| Bone Density | 1 | 2018 | 159 | 0.150 |
Why?
|
| Joint Diseases | 1 | 2017 | 37 | 0.150 |
Why?
|
| Vitamin D Deficiency | 1 | 2020 | 292 | 0.150 |
Why?
|
| Gastroesophageal Reflux | 1 | 2020 | 318 | 0.150 |
Why?
|
| Blood Transfusion | 2 | 2017 | 205 | 0.150 |
Why?
|
| Demography | 4 | 2021 | 279 | 0.150 |
Why?
|
| Administration, Topical | 2 | 2014 | 111 | 0.150 |
Why?
|
| Hospitalization | 3 | 2019 | 978 | 0.150 |
Why?
|
| Keratoconjunctivitis Sicca | 1 | 2017 | 1 | 0.150 |
Why?
|
| Mesenchymoma | 1 | 2017 | 4 | 0.150 |
Why?
|
| Cysts | 1 | 2018 | 70 | 0.150 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2020 | 235 | 0.150 |
Why?
|
| Piperazines | 1 | 2018 | 206 | 0.140 |
Why?
|
| Minocycline | 1 | 2017 | 61 | 0.140 |
Why?
|
| Social Support | 1 | 2020 | 423 | 0.140 |
Why?
|
| Opportunistic Infections | 1 | 2017 | 33 | 0.140 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 55 | 0.140 |
Why?
|
| Brain | 2 | 2007 | 2176 | 0.140 |
Why?
|
| Tongue Neoplasms | 1 | 2017 | 29 | 0.140 |
Why?
|
| Lens Capsule, Crystalline | 1 | 2017 | 39 | 0.140 |
Why?
|
| Universities | 1 | 2018 | 191 | 0.140 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2017 | 57 | 0.140 |
Why?
|
| Arthritis | 1 | 2017 | 53 | 0.140 |
Why?
|
| Singing | 1 | 2016 | 5 | 0.140 |
Why?
|
| Cricoid Cartilage | 1 | 2016 | 10 | 0.140 |
Why?
|
| Otologic Surgical Procedures | 2 | 2014 | 23 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2012 | 1745 | 0.140 |
Why?
|
| Hearing Loss, High-Frequency | 1 | 2016 | 16 | 0.140 |
Why?
|
| Otitis Media, Suppurative | 1 | 2016 | 4 | 0.140 |
Why?
|
| Pyridines | 1 | 2018 | 261 | 0.140 |
Why?
|
| Duane Retraction Syndrome | 1 | 2016 | 5 | 0.140 |
Why?
|
| Health Status Disparities | 1 | 2020 | 326 | 0.140 |
Why?
|
| Persons With Hearing Impairments | 1 | 2016 | 22 | 0.140 |
Why?
|
| Mandible | 2 | 2021 | 53 | 0.140 |
Why?
|
| Health Resources | 1 | 2017 | 76 | 0.140 |
Why?
|
| Occupational Diseases | 1 | 2016 | 68 | 0.140 |
Why?
|
| Implantable Neurostimulators | 1 | 2016 | 12 | 0.140 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 378 | 0.130 |
Why?
|
| Adenocarcinoma | 2 | 2018 | 475 | 0.130 |
Why?
|
| Carcinoma, Small Cell | 1 | 2016 | 53 | 0.130 |
Why?
|
| Stapes | 1 | 2015 | 7 | 0.130 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 772 | 0.130 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 331 | 0.130 |
Why?
|
| Child Protective Services | 1 | 2015 | 9 | 0.130 |
Why?
|
| Social Welfare | 1 | 2015 | 11 | 0.130 |
Why?
|
| Double-Blind Method | 3 | 2014 | 1738 | 0.130 |
Why?
|
| Hypertension | 1 | 2005 | 1535 | 0.130 |
Why?
|
| Medication Adherence | 1 | 2019 | 335 | 0.130 |
Why?
|
| Auditory Perception | 1 | 2016 | 89 | 0.130 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2015 | 10 | 0.130 |
Why?
|
| Suture Techniques | 1 | 2015 | 75 | 0.130 |
Why?
|
| Learning Curve | 1 | 2015 | 20 | 0.130 |
Why?
|
| Hypnotics and Sedatives | 1 | 2016 | 96 | 0.130 |
Why?
|
| Predictive Value of Tests | 5 | 2012 | 1465 | 0.130 |
Why?
|
| Nose Neoplasms | 1 | 2015 | 25 | 0.130 |
Why?
|
| Neuroectodermal Tumor, Melanotic | 1 | 2015 | 4 | 0.130 |
Why?
|
| Dexamethasone | 2 | 2014 | 150 | 0.130 |
Why?
|
| Maxillary Neoplasms | 1 | 2015 | 12 | 0.130 |
Why?
|
| Child Welfare | 1 | 2015 | 53 | 0.130 |
Why?
|
| Arthropathy, Neurogenic | 1 | 2015 | 1 | 0.130 |
Why?
|
| Hemophilia B | 1 | 2015 | 2 | 0.130 |
Why?
|
| Intraoperative Neurophysiological Monitoring | 1 | 2015 | 2 | 0.130 |
Why?
|
| Hemarthrosis | 1 | 2015 | 3 | 0.130 |
Why?
|
| Hemophilia A | 1 | 2015 | 9 | 0.130 |
Why?
|
| Musculoskeletal System | 1 | 2015 | 11 | 0.130 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2015 | 24 | 0.130 |
Why?
|
| Electrodes, Implanted | 1 | 2015 | 98 | 0.120 |
Why?
|
| Elective Surgical Procedures | 1 | 2015 | 95 | 0.120 |
Why?
|
| Developmental Disabilities | 2 | 2007 | 119 | 0.120 |
Why?
|
| Hedgehog Proteins | 1 | 2015 | 38 | 0.120 |
Why?
|
| Teaching | 1 | 2016 | 169 | 0.120 |
Why?
|
| Membrane Proteins | 2 | 2017 | 617 | 0.120 |
Why?
|
| Lip | 1 | 2014 | 12 | 0.120 |
Why?
|
| Arthralgia | 1 | 2015 | 30 | 0.120 |
Why?
|
| HLA Antigens | 1 | 2015 | 82 | 0.120 |
Why?
|
| Stem Cell Transplantation | 1 | 2015 | 58 | 0.120 |
Why?
|
| Internship and Residency | 1 | 2020 | 596 | 0.120 |
Why?
|
| Angiography | 2 | 2022 | 194 | 0.120 |
Why?
|
| Hearing Loss, Sudden | 1 | 2014 | 4 | 0.120 |
Why?
|
| Endolymphatic Sac | 1 | 2014 | 6 | 0.120 |
Why?
|
| Central Nervous System Depressants | 2 | 2007 | 182 | 0.120 |
Why?
|
| Photochemotherapy | 1 | 2015 | 59 | 0.120 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 567 | 0.120 |
Why?
|
| Students | 1 | 2016 | 233 | 0.120 |
Why?
|
| Sex Factors | 4 | 2021 | 1266 | 0.120 |
Why?
|
| Velopharyngeal Sphincter | 1 | 2014 | 7 | 0.120 |
Why?
|
| Skin Ulcer | 1 | 2014 | 19 | 0.120 |
Why?
|
| Hospitals, Urban | 1 | 2014 | 46 | 0.120 |
Why?
|
| Adenoids | 1 | 2014 | 15 | 0.120 |
Why?
|
| Brain Neoplasms | 1 | 2018 | 371 | 0.120 |
Why?
|
| Invasive Pulmonary Aspergillosis | 1 | 2014 | 3 | 0.120 |
Why?
|
| Thyroidectomy | 2 | 2011 | 31 | 0.120 |
Why?
|
| Radiotherapy, Conformal | 1 | 2014 | 24 | 0.120 |
Why?
|
| Facial Neoplasms | 1 | 2014 | 10 | 0.120 |
Why?
|
| Decompression, Surgical | 1 | 2014 | 55 | 0.120 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2014 | 30 | 0.120 |
Why?
|
| Colony Count, Microbial | 1 | 2014 | 77 | 0.120 |
Why?
|
| Tachycardia, Ventricular | 1 | 2015 | 153 | 0.120 |
Why?
|
| Sodium Chloride | 1 | 2014 | 136 | 0.120 |
Why?
|
| Leukotriene Antagonists | 1 | 2013 | 13 | 0.110 |
Why?
|
| Acute Disease | 3 | 2020 | 658 | 0.110 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 694 | 0.110 |
Why?
|
| Human papillomavirus 16 | 1 | 2013 | 23 | 0.110 |
Why?
|
| Anemia, Sickle Cell | 1 | 2017 | 364 | 0.110 |
Why?
|
| Vulnerable Populations | 1 | 2014 | 84 | 0.110 |
Why?
|
| Antibodies, Viral | 1 | 2014 | 110 | 0.110 |
Why?
|
| Confidence Intervals | 2 | 2013 | 242 | 0.110 |
Why?
|
| Nuclear Proteins | 1 | 2015 | 271 | 0.110 |
Why?
|
| Patient Compliance | 2 | 2016 | 402 | 0.110 |
Why?
|
| Longitudinal Studies | 2 | 2015 | 1054 | 0.110 |
Why?
|
| Proportional Hazards Models | 4 | 2018 | 792 | 0.110 |
Why?
|
| HIV Infections | 2 | 2018 | 791 | 0.110 |
Why?
|
| Iodine Radioisotopes | 1 | 2013 | 119 | 0.110 |
Why?
|
| Diphtheria-Tetanus-Pertussis Vaccine | 1 | 2012 | 4 | 0.110 |
Why?
|
| Sialorrhea | 1 | 2012 | 7 | 0.110 |
Why?
|
| Belgium | 1 | 2012 | 18 | 0.110 |
Why?
|
| Immunization, Secondary | 1 | 2012 | 17 | 0.110 |
Why?
|
| BCG Vaccine | 1 | 2012 | 12 | 0.110 |
Why?
|
| Multivariate Analysis | 4 | 2018 | 1046 | 0.110 |
Why?
|
| Camptothecin | 1 | 2012 | 39 | 0.110 |
Why?
|
| Emigration and Immigration | 1 | 2012 | 33 | 0.110 |
Why?
|
| Mutation | 2 | 2017 | 1213 | 0.110 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2015 | 163 | 0.110 |
Why?
|
| Tympanoplasty | 2 | 2022 | 13 | 0.100 |
Why?
|
| Inflammation | 3 | 2015 | 1030 | 0.100 |
Why?
|
| Postoperative Period | 3 | 2017 | 238 | 0.100 |
Why?
|
| 4-Aminobutyrate Transaminase | 1 | 2012 | 4 | 0.100 |
Why?
|
| Vigabatrin | 1 | 2012 | 8 | 0.100 |
Why?
|
| Nasal Septum | 1 | 2012 | 16 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 2077 | 0.100 |
Why?
|
| Everolimus | 1 | 2012 | 26 | 0.100 |
Why?
|
| Depressive Disorder | 1 | 2016 | 621 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 3 | 2012 | 2791 | 0.100 |
Why?
|
| Observer Variation | 4 | 2021 | 330 | 0.100 |
Why?
|
| Phenol | 1 | 2011 | 6 | 0.100 |
Why?
|
| Telemedicine | 1 | 2020 | 700 | 0.100 |
Why?
|
| Administration, Sublingual | 1 | 2011 | 15 | 0.100 |
Why?
|
| Body Weight | 3 | 2011 | 554 | 0.100 |
Why?
|
| ras Proteins | 1 | 2012 | 102 | 0.100 |
Why?
|
| Ablation Techniques | 1 | 2012 | 33 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2022 | 2223 | 0.100 |
Why?
|
| Growth and Development | 1 | 2011 | 4 | 0.100 |
Why?
|
| Nasal Sprays | 2 | 2021 | 11 | 0.100 |
Why?
|
| Glycerol | 1 | 2011 | 26 | 0.100 |
Why?
|
| Radiography | 2 | 2014 | 572 | 0.100 |
Why?
|
| Osmolar Concentration | 2 | 2008 | 134 | 0.100 |
Why?
|
| Allergens | 1 | 2011 | 54 | 0.100 |
Why?
|
| Catheter Ablation | 1 | 2013 | 229 | 0.100 |
Why?
|
| Health Personnel | 1 | 2014 | 286 | 0.100 |
Why?
|
| Skin | 1 | 2014 | 451 | 0.090 |
Why?
|
| Parents | 3 | 2022 | 312 | 0.090 |
Why?
|
| Hyoid Bone | 1 | 2010 | 10 | 0.090 |
Why?
|
| Sjogren's Syndrome | 1 | 2011 | 18 | 0.090 |
Why?
|
| Video-Assisted Surgery | 1 | 2010 | 6 | 0.090 |
Why?
|
| Acoustic Impedance Tests | 2 | 2021 | 11 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2015 | 334 | 0.090 |
Why?
|
| Algorithms | 2 | 2014 | 1196 | 0.090 |
Why?
|
| Electrosurgery | 1 | 2010 | 15 | 0.090 |
Why?
|
| Sciatic Nerve | 1 | 2010 | 26 | 0.090 |
Why?
|
| Glucocorticoids | 1 | 2012 | 222 | 0.090 |
Why?
|
| Tracheal Stenosis | 1 | 2010 | 21 | 0.090 |
Why?
|
| Health Policy | 1 | 2012 | 221 | 0.090 |
Why?
|
| Sensitivity and Specificity | 5 | 2018 | 1753 | 0.090 |
Why?
|
| Osteotomy | 1 | 2010 | 46 | 0.090 |
Why?
|
| Laryngostenosis | 1 | 2010 | 13 | 0.090 |
Why?
|
| Socioeconomic Factors | 3 | 2020 | 955 | 0.090 |
Why?
|
| Pharmaceutical Preparations | 1 | 2011 | 101 | 0.090 |
Why?
|
| Hearing Loss, Bilateral | 2 | 2020 | 13 | 0.090 |
Why?
|
| Facial Paralysis | 1 | 2010 | 25 | 0.090 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2012 | 411 | 0.090 |
Why?
|
| Steroids | 1 | 2011 | 84 | 0.090 |
Why?
|
| Benign Paroxysmal Positional Vertigo | 2 | 2020 | 6 | 0.090 |
Why?
|
| Pressure | 2 | 2021 | 252 | 0.090 |
Why?
|
| S-Nitrosoglutathione | 1 | 2011 | 87 | 0.090 |
Why?
|
| Recurrence | 3 | 2020 | 948 | 0.090 |
Why?
|
| Meglumine | 1 | 2010 | 16 | 0.090 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2018 | 536 | 0.090 |
Why?
|
| Inpatients | 2 | 2022 | 208 | 0.090 |
Why?
|
| Bone Screws | 1 | 2010 | 90 | 0.090 |
Why?
|
| Meningitis | 2 | 2020 | 23 | 0.090 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2010 | 36 | 0.090 |
Why?
|
| Arteriovenous Malformations | 1 | 2010 | 34 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 1 | 2012 | 511 | 0.090 |
Why?
|
| Gadolinium DTPA | 1 | 2010 | 48 | 0.090 |
Why?
|
| Ointments | 1 | 2009 | 15 | 0.090 |
Why?
|
| Neoplasm Grading | 2 | 2021 | 111 | 0.080 |
Why?
|
| Emergency Service, Hospital | 2 | 2022 | 711 | 0.080 |
Why?
|
| Vena Cava, Inferior | 1 | 2009 | 41 | 0.080 |
Why?
|
| Uvula | 1 | 2009 | 5 | 0.080 |
Why?
|
| Injections | 1 | 2009 | 119 | 0.080 |
Why?
|
| Stroke | 1 | 2022 | 2163 | 0.080 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 201 | 0.080 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 454 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 3 | 2017 | 504 | 0.080 |
Why?
|
| Organometallic Compounds | 1 | 2010 | 95 | 0.080 |
Why?
|
| Breast Neoplasms | 1 | 2018 | 1536 | 0.080 |
Why?
|
| Hypertrophy | 2 | 2022 | 89 | 0.080 |
Why?
|
| Enzyme Inhibitors | 1 | 2012 | 659 | 0.080 |
Why?
|
| Health Care Surveys | 1 | 2009 | 239 | 0.080 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2010 | 181 | 0.080 |
Why?
|
| Spinal Cord | 1 | 2010 | 244 | 0.080 |
Why?
|
| Self Efficacy | 1 | 2009 | 199 | 0.080 |
Why?
|
| Immunohistochemistry | 4 | 2014 | 1174 | 0.080 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2008 | 15 | 0.080 |
Why?
|
| Diabetes Complications | 1 | 2010 | 249 | 0.080 |
Why?
|
| Electronic Mail | 1 | 2008 | 29 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 848 | 0.080 |
Why?
|
| Anticonvulsants | 2 | 2007 | 223 | 0.080 |
Why?
|
| Intraoperative Complications | 2 | 2020 | 129 | 0.080 |
Why?
|
| Erythrocytes | 1 | 2008 | 137 | 0.080 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 2 | 2008 | 373 | 0.080 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 1140 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2015 | 2689 | 0.070 |
Why?
|
| Regional Medical Programs | 1 | 2007 | 22 | 0.070 |
Why?
|
| Hospital Charges | 2 | 2017 | 60 | 0.070 |
Why?
|
| Disabled Children | 1 | 2007 | 16 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2009 | 383 | 0.070 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 561 | 0.070 |
Why?
|
| Pain Measurement | 2 | 2020 | 328 | 0.070 |
Why?
|
| Pulmonary Artery | 1 | 2009 | 323 | 0.070 |
Why?
|
| Mouth | 2 | 2020 | 64 | 0.070 |
Why?
|
| Injections, Subcutaneous | 1 | 2007 | 87 | 0.070 |
Why?
|
| Body Mass Index | 3 | 2017 | 867 | 0.070 |
Why?
|
| Abdomen, Acute | 1 | 2007 | 14 | 0.070 |
Why?
|
| Drug Tolerance | 1 | 2007 | 80 | 0.070 |
Why?
|
| Critical Care | 1 | 2009 | 263 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2010 | 362 | 0.070 |
Why?
|
| Preoperative Care | 2 | 2006 | 275 | 0.070 |
Why?
|
| Child Development | 1 | 2007 | 102 | 0.070 |
Why?
|
| Animals | 6 | 2014 | 20881 | 0.070 |
Why?
|
| Tympanic Membrane | 2 | 2019 | 25 | 0.070 |
Why?
|
| Risk | 2 | 2020 | 563 | 0.070 |
Why?
|
| Insulin | 1 | 2010 | 619 | 0.070 |
Why?
|
| Mice | 3 | 2012 | 8474 | 0.070 |
Why?
|
| Temperature | 1 | 2008 | 341 | 0.070 |
Why?
|
| Blood Glucose | 1 | 2010 | 631 | 0.070 |
Why?
|
| Receptors, AMPA | 1 | 2007 | 99 | 0.070 |
Why?
|
| Eating | 1 | 2007 | 119 | 0.070 |
Why?
|
| Sex Distribution | 2 | 2018 | 274 | 0.070 |
Why?
|
| Stents | 1 | 2011 | 657 | 0.070 |
Why?
|
| Alcohol-Induced Disorders | 1 | 2005 | 5 | 0.070 |
Why?
|
| GABA Agonists | 1 | 2005 | 23 | 0.070 |
Why?
|
| Speech Reception Threshold Test | 2 | 2016 | 25 | 0.070 |
Why?
|
| Alcoholic Intoxication | 1 | 2006 | 61 | 0.060 |
Why?
|
| Radiation Dosage | 1 | 2008 | 419 | 0.060 |
Why?
|
| Synaptic Transmission | 1 | 2007 | 236 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2007 | 447 | 0.060 |
Why?
|
| Tongue | 2 | 2017 | 20 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2014 | 931 | 0.060 |
Why?
|
| Infant, Premature | 1 | 2007 | 284 | 0.060 |
Why?
|
| Drug Monitoring | 2 | 2019 | 107 | 0.060 |
Why?
|
| Coronary Disease | 1 | 2007 | 358 | 0.060 |
Why?
|
| Benzodiazepines | 1 | 2005 | 130 | 0.060 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2018 | 85 | 0.060 |
Why?
|
| Coronary Stenosis | 1 | 2007 | 246 | 0.060 |
Why?
|
| Heart Defects, Congenital | 2 | 2020 | 596 | 0.060 |
Why?
|
| Cross-Over Studies | 2 | 2019 | 260 | 0.060 |
Why?
|
| Spinal Cord Injuries | 1 | 2011 | 551 | 0.060 |
Why?
|
| Titanium | 2 | 2016 | 118 | 0.060 |
Why?
|
| Patient Selection | 2 | 2018 | 592 | 0.060 |
Why?
|
| Hemispherectomy | 1 | 2004 | 5 | 0.060 |
Why?
|
| Language Development Disorders | 1 | 2004 | 9 | 0.060 |
Why?
|
| Biomarkers | 2 | 2010 | 1593 | 0.060 |
Why?
|
| Transplantation, Homologous | 2 | 2015 | 242 | 0.060 |
Why?
|
| Movement Disorders | 1 | 2004 | 58 | 0.060 |
Why?
|
| Vaccines, Conjugate | 1 | 2023 | 11 | 0.050 |
Why?
|
| Trismus | 1 | 2022 | 3 | 0.050 |
Why?
|
| Rhinomanometry | 1 | 2022 | 2 | 0.050 |
Why?
|
| Turbinates | 1 | 2022 | 12 | 0.050 |
Why?
|
| Hospital Mortality | 2 | 2018 | 384 | 0.050 |
Why?
|
| Pneumococcal Vaccines | 1 | 2023 | 30 | 0.050 |
Why?
|
| Single-Blind Method | 2 | 2015 | 249 | 0.050 |
Why?
|
| Paralysis | 1 | 2022 | 35 | 0.050 |
Why?
|
| Myocardium | 1 | 2008 | 1204 | 0.050 |
Why?
|
| Atenolol | 1 | 2022 | 20 | 0.050 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2005 | 435 | 0.050 |
Why?
|
| Ear | 1 | 2022 | 12 | 0.050 |
Why?
|
| Sweat Glands | 1 | 2022 | 10 | 0.050 |
Why?
|
| Electric Power Supplies | 1 | 2022 | 26 | 0.050 |
Why?
|
| Mucins | 1 | 2022 | 22 | 0.050 |
Why?
|
| Calcium | 2 | 2008 | 929 | 0.050 |
Why?
|
| Otoacoustic Emissions, Spontaneous | 1 | 2022 | 19 | 0.050 |
Why?
|
| Propranolol | 1 | 2022 | 103 | 0.050 |
Why?
|
| Evoked Potentials, Auditory, Brain Stem | 1 | 2022 | 49 | 0.050 |
Why?
|
| Echocardiography, Doppler | 1 | 2021 | 87 | 0.050 |
Why?
|
| Histamine Antagonists | 1 | 2021 | 22 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2018 | 652 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2021 | 17 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 125 | 0.050 |
Why?
|
| Pathology, Surgical | 1 | 2021 | 4 | 0.050 |
Why?
|
| Operating Rooms | 1 | 2022 | 108 | 0.050 |
Why?
|
| Geography | 1 | 2021 | 80 | 0.050 |
Why?
|
| Gastrostomy | 2 | 2014 | 110 | 0.050 |
Why?
|
| Protective Clothing | 1 | 2021 | 12 | 0.050 |
Why?
|
| Carrageenan | 1 | 2021 | 7 | 0.050 |
Why?
|
| Parotitis | 1 | 2021 | 7 | 0.050 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2022 | 189 | 0.050 |
Why?
|
| Oils, Volatile | 1 | 2021 | 9 | 0.050 |
Why?
|
| Chlorhexidine | 1 | 2021 | 12 | 0.050 |
Why?
|
| Terpenes | 1 | 2021 | 18 | 0.050 |
Why?
|
| Salicylates | 1 | 2021 | 22 | 0.050 |
Why?
|
| Mohs Surgery | 1 | 2021 | 16 | 0.050 |
Why?
|
| Povidone-Iodine | 1 | 2021 | 16 | 0.050 |
Why?
|
| Trachea | 1 | 2001 | 48 | 0.050 |
Why?
|
| Cervical Plexus | 1 | 2020 | 2 | 0.050 |
Why?
|
| Exercise Therapy | 1 | 2022 | 183 | 0.050 |
Why?
|
| Delayed Diagnosis | 1 | 2021 | 39 | 0.050 |
Why?
|
| Fluorouracil | 2 | 2018 | 130 | 0.050 |
Why?
|
| Ciprofloxacin | 1 | 2020 | 30 | 0.050 |
Why?
|
| Midazolam | 1 | 2020 | 46 | 0.050 |
Why?
|
| Viruses | 1 | 2020 | 14 | 0.050 |
Why?
|
| Otoscopy | 1 | 2020 | 3 | 0.050 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 25 | 0.050 |
Why?
|
| Middle Ear Ventilation | 1 | 2020 | 7 | 0.050 |
Why?
|
| Air Pollutants, Occupational | 1 | 2020 | 7 | 0.050 |
Why?
|
| Viral Load | 1 | 2021 | 127 | 0.050 |
Why?
|
| Voice Quality | 1 | 2020 | 21 | 0.050 |
Why?
|
| Deglutition | 1 | 2023 | 221 | 0.040 |
Why?
|
| Sella Turcica | 1 | 2020 | 10 | 0.040 |
Why?
|
| Respiratory Tract Diseases | 1 | 2020 | 43 | 0.040 |
Why?
|
| Semicircular Canals | 1 | 2020 | 9 | 0.040 |
Why?
|
| Hydrogen Peroxide | 1 | 2021 | 168 | 0.040 |
Why?
|
| Fundoplication | 1 | 2020 | 27 | 0.040 |
Why?
|
| Goals | 1 | 2020 | 65 | 0.040 |
Why?
|
| Independent Living | 1 | 2020 | 44 | 0.040 |
Why?
|
| Critical Pathways | 1 | 2020 | 33 | 0.040 |
Why?
|
| Physician's Role | 1 | 2021 | 116 | 0.040 |
Why?
|
| Acoustics | 1 | 2020 | 20 | 0.040 |
Why?
|
| Cisplatin | 2 | 2018 | 192 | 0.040 |
Why?
|
| Hearing Loss, Conductive | 1 | 2020 | 12 | 0.040 |
Why?
|
| Hyperbilirubinemia | 1 | 2020 | 12 | 0.040 |
Why?
|
| Epilepsy | 1 | 2004 | 336 | 0.040 |
Why?
|
| Asphyxia Neonatorum | 1 | 2020 | 14 | 0.040 |
Why?
|
| Esophagitis | 1 | 2020 | 45 | 0.040 |
Why?
|
| Valsalva Maneuver | 1 | 2019 | 10 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2021 | 304 | 0.040 |
Why?
|
| Craniofacial Abnormalities | 1 | 2020 | 18 | 0.040 |
Why?
|
| Vibration | 1 | 2020 | 32 | 0.040 |
Why?
|
| Mass Screening | 1 | 2006 | 843 | 0.040 |
Why?
|
| Brain Abscess | 1 | 2019 | 7 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2001 | 247 | 0.040 |
Why?
|
| Hydrocephalus | 1 | 2020 | 40 | 0.040 |
Why?
|
| Random Allocation | 2 | 2011 | 442 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 67 | 0.040 |
Why?
|
| Biometry | 1 | 2020 | 72 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2019 | 30 | 0.040 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2019 | 20 | 0.040 |
Why?
|
| Translating | 1 | 2019 | 23 | 0.040 |
Why?
|
| Noise | 1 | 2021 | 153 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 53 | 0.040 |
Why?
|
| Specialization | 1 | 2019 | 66 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2007 | 2550 | 0.040 |
Why?
|
| Odds Ratio | 2 | 2014 | 880 | 0.040 |
Why?
|
| Electrocardiography | 2 | 2015 | 601 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 426 | 0.040 |
Why?
|
| Rare Diseases | 1 | 2019 | 41 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2020 | 172 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 109 | 0.040 |
Why?
|
| Occupational Exposure | 1 | 2020 | 122 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 101 | 0.040 |
Why?
|
| Medical Oncology | 1 | 2020 | 110 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2005 | 1451 | 0.040 |
Why?
|
| Triage | 1 | 2020 | 109 | 0.040 |
Why?
|
| Patient Care Team | 1 | 2021 | 311 | 0.040 |
Why?
|
| Epirubicin | 1 | 2018 | 4 | 0.040 |
Why?
|
| Capecitabine | 1 | 2018 | 11 | 0.040 |
Why?
|
| Epistaxis | 1 | 2018 | 6 | 0.040 |
Why?
|
| Denervation | 1 | 2018 | 23 | 0.040 |
Why?
|
| Adenoviridae Infections | 1 | 1998 | 6 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 265 | 0.040 |
Why?
|
| Leucovorin | 1 | 2018 | 35 | 0.040 |
Why?
|
| Mastectomy, Segmental | 1 | 2018 | 64 | 0.040 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2018 | 5 | 0.040 |
Why?
|
| Reference Values | 2 | 2011 | 579 | 0.040 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2018 | 12 | 0.040 |
Why?
|
| Sleep | 1 | 2020 | 263 | 0.040 |
Why?
|
| Neoadjuvant Therapy | 1 | 2018 | 104 | 0.040 |
Why?
|
| Histiocytosis, Langerhans-Cell | 1 | 2018 | 12 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2001 | 431 | 0.040 |
Why?
|
| Pediatric Obesity | 1 | 2020 | 92 | 0.040 |
Why?
|
| Language | 1 | 2019 | 120 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2019 | 381 | 0.040 |
Why?
|
| Rhabdomyosarcoma | 1 | 2018 | 36 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2020 | 211 | 0.040 |
Why?
|
| Oxygen | 1 | 2020 | 386 | 0.040 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 54 | 0.040 |
Why?
|
| Morbidity | 1 | 2018 | 130 | 0.040 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1998 | 123 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2019 | 215 | 0.040 |
Why?
|
| Breast | 1 | 2018 | 137 | 0.040 |
Why?
|
| Computed Tomography Angiography | 1 | 2022 | 424 | 0.040 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2017 | 35 | 0.040 |
Why?
|
| Operative Time | 1 | 2017 | 45 | 0.040 |
Why?
|
| Linear Models | 1 | 2019 | 521 | 0.040 |
Why?
|
| Age Distribution | 1 | 2018 | 320 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2020 | 294 | 0.040 |
Why?
|
| Neck | 1 | 2017 | 62 | 0.040 |
Why?
|
| Speech Production Measurement | 1 | 2017 | 14 | 0.040 |
Why?
|
| Artifacts | 2 | 2008 | 125 | 0.040 |
Why?
|
| Debridement | 1 | 2017 | 55 | 0.040 |
Why?
|
| Data Warehousing | 1 | 2017 | 21 | 0.040 |
Why?
|
| Cystic Fibrosis | 1 | 2001 | 283 | 0.040 |
Why?
|
| Colitis | 1 | 1998 | 156 | 0.040 |
Why?
|
| Periodicals as Topic | 1 | 2019 | 158 | 0.040 |
Why?
|
| Exercise | 1 | 2022 | 658 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2018 | 114 | 0.030 |
Why?
|
| Psychometrics | 1 | 2019 | 514 | 0.030 |
Why?
|
| Motor Activity | 2 | 2012 | 621 | 0.030 |
Why?
|
| Disease Management | 1 | 2018 | 248 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2008 | 546 | 0.030 |
Why?
|
| Oximetry | 1 | 2016 | 29 | 0.030 |
Why?
|
| Skin Transplantation | 1 | 2016 | 45 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 498 | 0.030 |
Why?
|
| Sensory Thresholds | 1 | 2016 | 50 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2011 | 2083 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2017 | 109 | 0.030 |
Why?
|
| Growth Disorders | 1 | 2015 | 21 | 0.030 |
Why?
|
| Reference Standards | 1 | 2015 | 115 | 0.030 |
Why?
|
| Exposure to Violence | 1 | 2015 | 19 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2016 | 99 | 0.030 |
Why?
|
| Social Adjustment | 1 | 2015 | 74 | 0.030 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2015 | 13 | 0.030 |
Why?
|
| Facial Nerve Injuries | 1 | 2015 | 4 | 0.030 |
Why?
|
| Synovitis | 1 | 2015 | 8 | 0.030 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 68 | 0.030 |
Why?
|
| von Willebrand Factor | 1 | 2015 | 47 | 0.030 |
Why?
|
| Metalloendopeptidases | 1 | 2015 | 67 | 0.030 |
Why?
|
| Biopsy | 1 | 2017 | 540 | 0.030 |
Why?
|
| Respiration | 1 | 2015 | 91 | 0.030 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 508 | 0.030 |
Why?
|
| Histocompatibility Testing | 1 | 2015 | 38 | 0.030 |
Why?
|
| Pediatrics | 1 | 2018 | 341 | 0.030 |
Why?
|
| Visual Analog Scale | 1 | 2014 | 8 | 0.030 |
Why?
|
| Rotation | 1 | 2014 | 58 | 0.030 |
Why?
|
| Educational Status | 1 | 2015 | 273 | 0.030 |
Why?
|
| Speech Discrimination Tests | 1 | 2014 | 17 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 2014 | 25 | 0.030 |
Why?
|
| Ethmoid Sinus | 1 | 1994 | 15 | 0.030 |
Why?
|
| Prednisolone | 1 | 2014 | 23 | 0.030 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 1994 | 23 | 0.030 |
Why?
|
| Tolonium Chloride | 1 | 2014 | 3 | 0.030 |
Why?
|
| Sclerosis | 1 | 2014 | 32 | 0.030 |
Why?
|
| Hematologic Diseases | 1 | 2014 | 20 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2008 | 1040 | 0.030 |
Why?
|
| Ankle Joint | 1 | 2015 | 57 | 0.030 |
Why?
|
| Cytodiagnosis | 1 | 2014 | 20 | 0.030 |
Why?
|
| Cheek | 1 | 2014 | 11 | 0.030 |
Why?
|
| Interleukins | 1 | 2014 | 79 | 0.030 |
Why?
|
| Prednisone | 1 | 2014 | 104 | 0.030 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 180 | 0.030 |
Why?
|
| Disease Progression | 1 | 2017 | 1038 | 0.030 |
Why?
|
| Pregnancy | 1 | 2020 | 2334 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 2014 | 144 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 2014 | 82 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2014 | 36 | 0.030 |
Why?
|
| Mouth Mucosa | 1 | 2014 | 51 | 0.030 |
Why?
|
| Methylprednisolone | 1 | 2014 | 99 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2015 | 135 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2014 | 139 | 0.030 |
Why?
|
| Organ Size | 1 | 2014 | 242 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2014 | 191 | 0.030 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2013 | 6 | 0.030 |
Why?
|
| Child Abuse | 1 | 2015 | 186 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2015 | 115 | 0.030 |
Why?
|
| Physical Examination | 1 | 2014 | 152 | 0.030 |
Why?
|
| Phenotype | 1 | 2016 | 947 | 0.030 |
Why?
|
| Forced Expiratory Volume | 1 | 2013 | 87 | 0.030 |
Why?
|
| Mental Health | 1 | 2015 | 278 | 0.030 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2013 | 56 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2015 | 453 | 0.030 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2012 | 25 | 0.030 |
Why?
|
| Health Status | 1 | 2015 | 429 | 0.030 |
Why?
|
| Rats | 2 | 2011 | 5300 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2012 | 201 | 0.030 |
Why?
|
| Dissection | 1 | 2012 | 29 | 0.030 |
Why?
|
| Equipment Reuse | 1 | 2012 | 7 | 0.030 |
Why?
|
| Clinical Coding | 1 | 2012 | 21 | 0.030 |
Why?
|
| Adaptation, Psychological | 1 | 2015 | 447 | 0.030 |
Why?
|
| Insurance Claim Review | 1 | 2012 | 39 | 0.030 |
Why?
|
| Thyroiditis | 1 | 2011 | 5 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2012 | 260 | 0.020 |
Why?
|
| Weight Loss | 1 | 2014 | 319 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 306 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 2012 | 124 | 0.020 |
Why?
|
| Nervous System | 1 | 2011 | 45 | 0.020 |
Why?
|
| Body Height | 1 | 2011 | 67 | 0.020 |
Why?
|
| Edema | 1 | 2011 | 66 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 438 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 710 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2012 | 239 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 137 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2015 | 753 | 0.020 |
Why?
|
| Cranial Fossa, Middle | 1 | 2010 | 8 | 0.020 |
Why?
|
| Empty Sella Syndrome | 1 | 2010 | 10 | 0.020 |
Why?
|
| Electrocoagulation | 1 | 2010 | 35 | 0.020 |
Why?
|
| Meningocele | 1 | 2010 | 12 | 0.020 |
Why?
|
| Failure to Thrive | 1 | 2010 | 17 | 0.020 |
Why?
|
| Pneumonia, Aspiration | 1 | 2010 | 22 | 0.020 |
Why?
|
| Tracheotomy | 1 | 2010 | 17 | 0.020 |
Why?
|
| Self Administration | 1 | 2012 | 419 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2012 | 332 | 0.020 |
Why?
|
| Conditioning, Operant | 1 | 2012 | 241 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2015 | 1851 | 0.020 |
Why?
|
| Dura Mater | 1 | 2010 | 23 | 0.020 |
Why?
|
| Pseudotumor Cerebri | 1 | 2010 | 43 | 0.020 |
Why?
|
| Mental Disorders | 1 | 2015 | 659 | 0.020 |
Why?
|
| Mast Cells | 1 | 2010 | 113 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 306 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 500 | 0.020 |
Why?
|
| Microcirculation | 1 | 2008 | 77 | 0.020 |
Why?
|
| Neuroprotective Agents | 1 | 2011 | 317 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2008 | 132 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2008 | 215 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 160 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2010 | 344 | 0.020 |
Why?
|
| Coronary Artery Bypass | 1 | 2008 | 218 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2007 | 107 | 0.020 |
Why?
|
| South Carolina | 1 | 2014 | 2752 | 0.020 |
Why?
|
| Personal Satisfaction | 1 | 2007 | 123 | 0.020 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2006 | 37 | 0.020 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2006 | 27 | 0.020 |
Why?
|
| Health Surveys | 1 | 2007 | 489 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2006 | 114 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2006 | 193 | 0.020 |
Why?
|
| Transferrin | 1 | 2006 | 94 | 0.020 |
Why?
|
| Plasma Substitutes | 1 | 2004 | 15 | 0.010 |
Why?
|
| Brain Damage, Chronic | 1 | 2004 | 25 | 0.010 |
Why?
|
| Epilepsies, Partial | 1 | 2004 | 24 | 0.010 |
Why?
|
| Encephalitis | 1 | 2004 | 43 | 0.010 |
Why?
|
| Blood Loss, Surgical | 1 | 2004 | 79 | 0.010 |
Why?
|
| Cerebral Infarction | 1 | 2004 | 103 | 0.010 |
Why?
|
| Heart | 1 | 2008 | 850 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2008 | 2673 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2006 | 334 | 0.010 |
Why?
|
| G(M1) Ganglioside | 1 | 2001 | 8 | 0.010 |
Why?
|
| Egtazic Acid | 1 | 2001 | 29 | 0.010 |
Why?
|
| Thapsigargin | 1 | 2001 | 18 | 0.010 |
Why?
|
| Adhesins, Bacterial | 1 | 2001 | 13 | 0.010 |
Why?
|
| Spectrophotometry | 1 | 2001 | 54 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2001 | 71 | 0.010 |
Why?
|
| Cerebral Cortex | 1 | 2004 | 415 | 0.010 |
Why?
|
| Luciferases | 1 | 2001 | 105 | 0.010 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2001 | 51 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2001 | 191 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2001 | 150 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2001 | 147 | 0.010 |
Why?
|
| Primary Health Care | 1 | 2006 | 703 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2001 | 261 | 0.010 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2001 | 133 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2001 | 250 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 2001 | 248 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 1047 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2001 | 791 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2001 | 432 | 0.010 |
Why?
|
| Lipopolysaccharides | 1 | 2001 | 455 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2001 | 954 | 0.010 |
Why?
|
| Brain Ischemia | 1 | 2004 | 665 | 0.010 |
Why?
|
| Cytomegalovirus Infections | 1 | 1998 | 69 | 0.010 |
Why?
|
| Adenoviridae | 1 | 1998 | 295 | 0.010 |
Why?
|
| Cell Line | 1 | 2001 | 1752 | 0.010 |
Why?
|
| Lung | 1 | 2001 | 849 | 0.010 |
Why?
|
| Actuarial Analysis | 1 | 1994 | 23 | 0.010 |
Why?
|
| Remission Induction | 1 | 1994 | 111 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 1994 | 129 | 0.010 |
Why?
|